MetLife Investment Management’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-18,318
| Closed | -$1.97M | – | 3016 |
|
|
2023
Q1 | $1.97M | Hold |
18,318
| – | – | 0.01% | 917 |
|
|
2022
Q4 | $2.01M | Buy |
18,318
+854
| +5% | +$93.9K | 0.02% | 894 |
|
|
2022
Q3 | $1.03M | Hold |
17,464
| – | – | 0.01% | 1173 |
|
|
2022
Q2 | $493K | Hold |
17,464
| – | – | ﹤0.01% | 1674 |
|
|
2022
Q1 | $659K | Buy |
17,464
+6,227
| +55% | +$235K | ﹤0.01% | 1608 |
|
|
2021
Q4 | $444K | Buy |
11,237
+6,326
| +129% | +$250K | ﹤0.01% | 1572 |
|
|
2021
Q3 | $116K | Buy |
+4,911
| New | +$116K | ﹤0.01% | 2373 |
|